292 related articles for article (PubMed ID: 17875049)
41. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease.
Rahman I; van Schadewijk AA; Crowther AJ; Hiemstra PS; Stolk J; MacNee W; De Boer WI
Am J Respir Crit Care Med; 2002 Aug; 166(4):490-5. PubMed ID: 12186826
[TBL] [Abstract][Full Text] [Related]
42. Detection and prevalence of chronic obstructive pulmonary disease in a cardiovascular clinic: evaluation using a hand held FEV₁/FEV₆ meter and questionnaire.
Wada H; Nakano Y; Nagao T; Osawa M; Yamada H; Sakaguchi C; Matsumoto T; Tsutamoto T; Ito M; Horie M
Respirology; 2010 Nov; 15(8):1252-8. PubMed ID: 20920134
[TBL] [Abstract][Full Text] [Related]
43. Treatment of COPD: moving beyond the lungs.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Curr Opin Pharmacol; 2012 Jun; 12(3):315-22. PubMed ID: 22552103
[TBL] [Abstract][Full Text] [Related]
44. Co-morbidity in mild-to-moderate COPD: comparison to normal and restrictive lung function.
Lindberg A; Larsson LG; Rönmark E; Lundbäck B
COPD; 2011 Dec; 8(6):421-8. PubMed ID: 22149402
[TBL] [Abstract][Full Text] [Related]
45. Defining the relationship between COPD and CVD: what are the implications for clinical practice?
Morgan AD; Zakeri R; Quint JK
Ther Adv Respir Dis; 2018; 12():1753465817750524. PubMed ID: 29355081
[TBL] [Abstract][Full Text] [Related]
46. Targeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities.
Bernardo I; Bozinovski S; Vlahos R
Pharmacol Ther; 2015 Nov; 155():60-79. PubMed ID: 26297673
[TBL] [Abstract][Full Text] [Related]
47. [Chronic respiratory diseases and atherosclerosis].
Teramoto S; Akashi S
Nihon Rinsho; 2011 Jan; 69(1):158-62. PubMed ID: 21226277
[TBL] [Abstract][Full Text] [Related]
48. [Cardiovascular comorbidity in COPD].
Cataluña JJ; García MA
Arch Bronconeumol; 2009; 45 Suppl 4():18-23. PubMed ID: 20116745
[TBL] [Abstract][Full Text] [Related]
49. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease.
Vanfleteren LE; Spruit MA; Groenen M; Gaffron S; van Empel VP; Bruijnzeel PL; Rutten EP; Op 't Roodt J; Wouters EF; Franssen FM
Am J Respir Crit Care Med; 2013 Apr; 187(7):728-35. PubMed ID: 23392440
[TBL] [Abstract][Full Text] [Related]
50. Increased DNA damage in patients with chronic obstructive pulmonary disease who had once smoked or been exposed to biomass.
Ceylan E; Kocyigit A; Gencer M; Aksoy N; Selek S
Respir Med; 2006 Jul; 100(7):1270-6. PubMed ID: 16307872
[TBL] [Abstract][Full Text] [Related]
51. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms.
Rahman I
Cell Biochem Biophys; 2005; 43(1):167-88. PubMed ID: 16043892
[TBL] [Abstract][Full Text] [Related]
52. [The continuum of COPD and cardiovascular risk: A global scenario of disease].
Názara Otero CA; Baloira Villar A
Clin Investig Arterioscler; 2015; 27(3):144-7. PubMed ID: 25496655
[TBL] [Abstract][Full Text] [Related]
53. Cardiovascular risk, chronic obstructive pulmonary disease and pulmonary rehabilitation: Can we learn from cardiac rehabilitation?
Triest FJ; Singh SJ; Vanfleteren LE
Chron Respir Dis; 2016 Aug; 13(3):286-94. PubMed ID: 27081189
[TBL] [Abstract][Full Text] [Related]
54. Association between chronic obstructive pulmonary disease and lung cancer: the missing link.
Wang ZL
Chin Med J (Engl); 2013 Jan; 126(1):154-65. PubMed ID: 23286495
[TBL] [Abstract][Full Text] [Related]
55. [Cardiovascular and chronic obstructive pulmonary diseases: pathophysiological processes and treatment tactics].
Ambatiello LG; Chazova IE
Ter Arkh; 2020 Apr; 92(3):78-83. PubMed ID: 32598797
[TBL] [Abstract][Full Text] [Related]
56. Systemic manifestations of COPD.
Murali Mohan BV; Sen T; Ranganath R
J Assoc Physicians India; 2012 Feb; 60 Suppl():44-7. PubMed ID: 23155812
[No Abstract] [Full Text] [Related]
57. [Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study].
de Lucas-Ramos P; Izquierdo-Alonso JL; Rodríguez-González Moro JM; Bellón-Cano JM; Ancochea-Bermúdez J; Calle-Rubio M; Calvo-Corbella E; Molina-París J; Pérez-Rodríguez E; Pons S
Arch Bronconeumol; 2008 May; 44(5):233-8. PubMed ID: 18448013
[TBL] [Abstract][Full Text] [Related]
58. The role of statins in chronic obstructive pulmonary disease: is cardiovascular disease the common denominator?
Amariei DE; Reed RM
Curr Opin Pulm Med; 2019 Mar; 25(2):173-178. PubMed ID: 30418244
[TBL] [Abstract][Full Text] [Related]
59. Why are people with "poor lung function" at increased atherothrombotic risk? A critical review with potential therapeutic indications.
Fimognari FL; Scarlata S; Antonelli-Incalzi R
Curr Vasc Pharmacol; 2010 Jul; 8(4):573-86. PubMed ID: 19485925
[TBL] [Abstract][Full Text] [Related]
60. Systemic consequences of COPD.
Tkác J; Man SF; Sin DD
Ther Adv Respir Dis; 2007 Oct; 1(1):47-59. PubMed ID: 19124347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
